RESUMO
Objective:To analyze the association between the Charlson Comorbidity Index(CCI)and the risk of early in-hospital death in cerebral hemorrhage inpatients.Methods:Basic personal and medical information about sex, age, surgery, frequency of hospitalization, days of hospitalization, and ICD-10 diagnosis code was collected for intracerebral hemorrhage patients aged 60 or above admitted to a tertiary general hospital from January 1, 2017 to December 31, 2019.The CCI score was calculated based on diagnoses at the time of discharge.Using the CCI score as the dependent variable and in-hospital death as the independent variable, univariate and multiple logistic regression analysis was conducted to examine the association between CCI and in-hospital death.The receiver operator characteristic curve(ROC)was used to assess the value of CCI in predicting death.Results:A total of 504 cerebral hemorrhage inpatients were included in the study, with an average age of 69.48±7.55 years, and 52 died during the period.Univariate Logistic regression showed that, compared with inpatients with CCI=3, the OR values(95% CI)for inpatients with CCI=4 and CCI≥5 were 2.145(1.056-4.355)and 4.769(2.168-10.494), respectively.Multiple Logistic regression showed that, compared with inpatients with CCI=3, the OR(95% CI)for inpatients with CCI≥5 was 4.453(1.474-13.456), The area under the ROC curve was 0.718, with 95% CI at 0.642-0.793( P<0.001). Conclusions:The CCI score was associated with the risk of early in-hospital death in elderly patients with cerebral hemorrhage and can be used to assess and predict the risk of early in-hospital death for these patients.
RESUMO
Antiviral therapy is the most important treatment for chronic hepatitis C.This paper reviews the progress in antiviral treatment o-ver recent years,including the combination therapy with polyethylene glycol-Interferon (PEG-IFN)and ribavirin (RBV),specific target therapy,and gene therapy.The paper believes that the anti-hepatitis C virus treatment needs more effective drug combination therapies, shorter courses,less side effect,higher drug resistance threshold,etc.
RESUMO
Objective To investigate the clinical efficacy of adefovir dipivoxil in antiviral treatment of chronic hepatitis B and its effect on peripheral blood T lymphocyte subsets.Methods 40 cases of patients with chronic hepatitis B were selected from The Fourth People’s Hospital of Qinghai in October 2009 to June 2012,the patients were given the antiviral treatment of adefovir dipivoxil.Before treatment,3 months,6 months and 12 months after treatment,the changes of liver function indicators of alanine transaminase(ALT),aspartate transaminase(AST)and total bilirubin(TBiL),and hepatitis B virus-DNA(HBV-DNA)were recorded;the total effective rate was observed;the peripheral blood T lymphocyte subsets changes was tested and analyzed by flow cytometry.Results The ALT,AST and TBiL of the patients all improved good,and the indicators of ALT,AST and TBiL after 12 months decreased significantly than before treatment,the HBV-DNA testing of the patients recovered negative,the difference was statistically significant (P<0.05 );the total effective rate of hepatitis B patients is 92.5%;the peripheral blood T lymphocyte subsets has no significant improvement in patients after antiviral treatment for 3 months.After the treatment for 6 months and 12 months,the CD4 +T and CD4 +/CD8 +T were significantly higher than those before treatment,there was no significant changes in CD3 +T and CD8 +T before and after treatment.Conclusion Adefovir dipivoxil has a good clinical efficacy in antiviral treatment of chronic hepatitis B,and can significantly improve the patients’liver function,improve peripheral blood T lymphocyte subsets imbalance.